Advertisement

Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia

      Anemia, defined by the World Health Organization as hemoglobin (Hb) levels <13.0 g/100 ml in male adults and <12.0 g/100 ml in female adults, is a common co-morbidity in heart failure (HF) with reduced ejection fraction (HFrEF), affecting up to two-thirds of all patients.
      • Aggarwal P
      • Sinha SK
      • Khanra D
      • Razi M
      • Nath RK
      • Shrivastava A.
      Hematinic deficiency in patients with heart failure with reduced ejection fraction (HFrEF).
      The most common contributing factor of anemia in HFrEF is iron deficiency, with the establishment of intravenous iron supplementation as an appropriate treatment strategy for such patients.
      • Chopra VK
      • Anker SD.
      Anaemia, iron deficiency and heart failure in 2020: facts and numbers.
      Anemia is associated with a significant increase in the risk for death or hospitalization for HF in patients with HFrEF by 14%, as demonstrated in a large cohort of patients with HF from the Swedish HF registry.
      • Savarese G
      • Jonsson Å
      • Hallberg AC
      • Dahlström U
      • Edner M
      • Lund LH.
      Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aggarwal P
        • Sinha SK
        • Khanra D
        • Razi M
        • Nath RK
        • Shrivastava A.
        Hematinic deficiency in patients with heart failure with reduced ejection fraction (HFrEF).
        Ann Cardiol Angeiol (Paris). 2022; 71: 153-159
        • Chopra VK
        • Anker SD.
        Anaemia, iron deficiency and heart failure in 2020: facts and numbers.
        ESC Heart Fail. 2020; 7: 2007-2011
        • Savarese G
        • Jonsson Å
        • Hallberg AC
        • Dahlström U
        • Edner M
        • Lund LH.
        Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.
        Int J Cardiol. 2020; 298: 59-65
        • Zannad F
        • Ferreira JP
        • Pocock SJ
        • Anker SD
        • Butler J
        • Filippatos G
        • Brueckmann M
        • Ofstad AP
        • Pfarr E
        • Jamal W
        • Packer M.
        SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
        Lancet. 2020; 396: 819-829
        • Kanbay M
        • Tapoi L
        • Ureche C
        • Tanriover C
        • Cevik E
        • Demiray A
        • Afsar B
        • Cherney DZI
        • Covic A
        Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
        Int Urol Nephrol. 2022; 54: 827-841
        • Fitchett D
        • Inzucchi SE
        • Zinman B
        • Wanner C
        • Schumacher M
        • Schmoor C
        • Ohneberg K
        • Ofstad AP
        • Salsali A
        • George JT
        • Hantel S
        • Bluhmki E
        • Lachin JM
        • Zannad F
        Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
        ESC Heart Fail. 2021; 8: 4517-4527
        • Ferreira JP
        • Anker SD
        • Butler J
        • Filippatos G
        • Iwata T
        • Salsali A
        • Zeller C
        • Pocock SJ
        • Zannad F
        • Packer M
        Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
        Eur J Heart Fail. 2022; 24: 708-715
        • Docherty KF
        • Curtain JP
        • Anand IS
        • Bengtsson O
        • Inzucchi SE
        • Køber L
        • Kosiborod MN
        • Langkilde AM
        • Martinez FA
        • Ponikowski P
        • Sabatine MS
        • Schou M
        • Sjöstrand M
        • Solomon SD
        • Jhund PS
        • McMurray JJV
        • DAPA-HF Investigators and Committees
        Effect of dapagliflozin on anaemia in DAPA-HF.
        Eur J Heart Fail. 2021; 23: 617-628